However, the PARAMOUNT study (Prospective Comparison of ARNI [angiotensin receptor‐neprilysin inhibitor] with ARB on Management of Heart Failure with Preserved Ejection Fraction) trial reported that this combination impacts renal function as shown by an increase in urinary albumin to creatinine ratio (UACR)‐mediated through the effects of increased bioavailability of natriuretic peptides (NPs) by NEP inhibition (Voors et al., 2015). The gene discussed is ALB; the disease is heart failure.